Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00855894
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00833963
- Locations
- 🇺🇸
Kendle International, Inc, Wilmington, North Carolina, United States
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT00781612
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comp Cancer Centers of Nevada, Los Angeles, California, United States
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT00567190
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸LAC USC Medical Center, Los Angeles, California, United States
🇺🇸St. Barnabas Cancer Center, Livingston, New Jersey, United States
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 417
- Registration Number
- NCT00545688
- Locations
- 🇦🇺
Geelong Hospital; Andrew Love Cancer Centre, Geelong, Victoria, Australia
🇲🇽ARKE Estudios Clínicos S.A. de C.V., Mexico City, Mexico
🇮🇱Meir Medical Center; Oncology, Kfar-Saba, Israel
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00096941
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00096993
- Locations
- 🇺🇸
Carle Clinic Association, Urbana, Illinois, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT00063154
- Locations
- 🇺🇸
Memorial-Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.